Prevalence of vulvovaginal candidiasis among pregnant women in Africa: A systematic review and meta-analysis

Ahmed Osman Mohamed1,2, Malik Suliman Mohamed3,4, Tauqeer Hussain Mallhi5, Mohamed Abdelrahman Hussain1, Mohammad Ali Jalloh1, Khatib Ali Omar1, Manasik Omar Alhaj6, Alaa Aldeen Makki Mohamed Ali7

1 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, International University of Africa, Khartoum, Sudan
2 Department of Pharmaceutics, Faculty of Pharmacy, Sudan International University, Khartoum, Sudan
3 Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Al-Jouf Province, Kingdom of Saudi Arabia
4 Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Sudan
5 Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Al-Jouf Province, Kingdom of Saudi Arabia
6 School of Health Science, Ahfad University for Women, Khartoum, Sudan
7 Department of Pharmacology and Pharmacy Practice, Faculty of Pharmacy, Karary University, Khartoum, Sudan

Abstract

Introduction: Vulvovaginal candidiasis (VVC) is a superficial yeast infection of the vulva and/or vagina. It is mostly caused by an overgrowth of the commensal pathogen Candida species [1]. C. albicans was known to be the primary pathogen responsible for the infection, however, an epidemiological shift toward Non-Candida albicans (NCA) is now observed across the globe [2]. Other species such as C. glabrata, C. krusei, and C. parapsilosis are emerging causative agents and in some clinical settings in a higher proportion than C. albicans. Alarmingly, co-infection of C. albicans and NCA has been also reported [3,4].

There are several risk factors implicated in the development of VVC. Physiological changes associated with pregnancy -most importantly increased estrogen level- increase the risk to develop VVC from 20% among non-pregnant women to 30% during pregnancy [5]. A previous study also showed that approximately 70% to 75% of women above the age of 18 suffer at
least one attack of Candida vaginosis in their lifetime. Some women were affected only once in their lifetime, while others were affected occasionally with a varying degree of severity, with the development of chronic or recurrent VVC [6]. Furthermore, another estimate showed that 8% to 10% of adult women are susceptible to recurrent VVC [5].

To the best of our knowledge, previous regional and international meta-analyses provide insight into bacterial vaginosis (BV) and sexually transmitted infections (STIs) among women [7]. However, these studies present limited data on the occurrence of VVC among pregnant women. These studies have discussed the high risks of various vaginal infections. Of these, one quantitative synthesis of 18 HIV prevention studies indicated the prevalence of BV is 40% [7]. Another systematic review on 86 studies showed a relatively higher prevalence of BV in African women as compared to women from Asia and America [8]. Several epidemiological studies have shown the impact of intrauterine infection in preterm birth. Goldenberg et al. reported that nearly 40% of preterm birth were caused by either bacterial or fungal vaginal infections [9]. Roberts et al. declared that congenital cutaneous candidiasis has been associated with VVC, while the preventable and controlled measures of VVC have been successfully associated with a low incidence of preterm birth [10].

Since Candida species are the most common attributor of vaginal infection during pregnancy such as VVC, understanding the epidemiology of VVC is expected to build a foundation for improving the diagnostic tools as well as providing better therapeutic guidelines. In this context, this meta-analysis was conducted to ascertain the pooled prevalence of VVC among pregnant women in African countries and to stratify the prevalence by regions, years, and causative agents. Furthermore, the study aims at suggesting possible reasons that might contribute to the epidemiological diversity across the countries whenever possible.

**Methods**

**Information sources**

A literature search was conducted by two independent reviewers using electronic databases (PubMed, Scopus, Science-Direct, and Google Scholar) from the date of inception to December 2020. The PubMed search strategy served as a reference for the development of search strategies for the other databases. The search terms used were (“prevalence” OR “epidemiology” OR “rate”) AND (“Vaginal infection” OR “Vulvovaginal Candidiasis”) AND (“pregnant woman”) AND (“Africa”). A manual search for each African country was also included. The reference list of each study along with grey literature was also searched to identify the potential studies. The search included only published articles and was limited to human studies regardless of the age group.

**Inclusion criteria**

The observational studies evaluating the prevalence of VVC were included in this review. The studies conducted in one of the African countries and answered the review question were included in the qualitative and quantitative synthesis of results.

**Exclusion criteria**

All the studies on symptomatic pregnant women and those conducted outside of African regions were excluded from this review. Moreover, all the studies other than cross-sectional studies and those with non-extractable data were also excluded from the analysis.

**Data extraction**

Two researchers independently screened all titles and abstracts retrieved from the electronic databases. The full text of each potentially eligible article was obtained and screened independently to ascertain whether it meets the inclusion criteria or not. The required results from each study were collected using a data collection form. Any conflict or deviation was solved through mutual consultation and concurrence.
Study selection

A total of 1,226 studies were initially identified and considered potentially relevant. Of these, 85 studies were duplicates, and 1,102 did not meet the inclusion criteria. Thirty-nine studies were evaluated in detail to determine whether they described the prevalence of VVC among pregnant women. Of these, 16 studies were included in qualitative and quantitative synthesis of results. Figure 1 illustrates the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of study selection.

Quality assessment

The quality appraisal of the included studies was carried out by Joanna Briggs Institute (JBI) Critical Appraisal Checklist for epidemiological studies. This checklist assesses the methodological quality and the possibility of bias through eight items, where each item has four possible answers: yes, no, unclear, and not applicable. The quality assessment of each study is described in Supplementary Table 1. Publication bias was assessed qualitatively through the funnel plot.

Quantitative synthesis and Analysis

The sample size and cases from each study were used to pool the prevalence. A random-effects model was assumed using the DerSimonian-Laird approach with Freeman-Tukey double arcsine transformed proportion at 95% CI. All statistical analyses were done using the Open-Meta software. The $I^2$ statistic was used to assess heterogeneity across the included studies.

Results

Selection and descriptive characteristics of the studies

Our search reported 16 studies across eight African countries (Figure 2). These studies followed a cross-sectional design and were published between 1996 and 2020. Six studies were from Nigeria, 2 each from Sudan, Kenya, and Ghana, and one report each from Ethiopia, Burkina-Faso, Togo, and Uganda. The cumulative sample size was 4,158 which varied from 100 to 589 across these studies. A detailed description of the study characteristics is given in Table 1.

Prevalence of VVC

The pooled prevalence of VVC using the random-effect model was 29.1% (CI 95%: 24.8 – 33.5), lowest (14%) in Sudan, and highest (45.4%) in Uganda. Significant heterogeneity was observed across these studies ($I^2 = 89.8\%$ and $p < 0.001$). The pooled prevalence and prevalence of each individual study is shown in Figure 3.

Risk of Bias Assessment

The risk of bias of individual studies using JBI critical appraisal for studies reporting prevalence data is shown in Supplementary Table 1. The funnel plot was inspected visually for symmetry (equal dots on both sides), indicating the absence of publication bias, regression test for funnel asymmetry was indicated ($p = 0.272$). The funnel plot of Double arcsine transformed proportion and standard error is shown in Figure 4.

Assessment of heterogeneity

The heterogeneity was found to be significant across the 16 included studies ($I^2 = 89.8\%$). Subgroup and meta-regression analyses were conducted ascertain the source of heterogeneity.
Subgroup analyses

A subgroup analysis based on African sub-regions was conducted to stratify the studies into three regions; North, East, and West, while there were no studies from Southern and Central Africa. A relatively higher prevalence (29.5%) was reported in Eastern Africa (4 studies) and heterogeneity remains to be high ($I^2 = 59.95\%$). On the other hand, studies from North Africa (2 studies) were homogenous ($I^2 = 0.00\%$) with a low prevalence (15.3%). The majority of the studies (10 studies) were conducted in Western Africa where prevalence was found to be 29.9% ($P^2 = 94.7\%$). The subgroup analysis based on different African regions is shown in Figure 5.

Moderator analysis

Further heterogeneity investigation was carried out using mixed-effect meta-regression based on year of publication, sample size, and method of detection.

Continuous variables were considered for both types of analysis. The moderator analysis indicated that studies that adopted methods or techniques that were able to detect all or most of the possible species reported a higher prevalence in comparison to studies that screened only one specie, the association was found to be statistically significant ($p \leq 0.001$). The sample size aids in explaining the heterogeneity as a significant relationship was found between the effect size and the sample size ($p = 0.049$), indicating that the studies with a higher sample size reported a higher prevalence of VVC. The year of publication was not significantly correlated with the effect size ($p = 0.316$). Meta-regression analysis is provided in Table 2 (Meta-regression figures are provided in Supplementary Figures 1 and 2).

Discussion

This study is the first of its kind to underscore the available literature on the epidemiology of VVC among pregnant African women. Moreover, the current study

Table 1. Characteristics of the included studies.

| S. No. | Study ID | Year | Country | Sample selection | Sample size | Prevalence of VVC (%) | Ref |
|-------|----------|------|---------|-----------------|-------------|----------------------|-----|
| 1     | Okonkwo  | 2010 | Nigeria | All             | 300         | 30%                  | [11]|
| 2     | Donbraye | 2010 | Nigeria | All             | 100         | 26%                  | [12]|
| 3     | Ezeigbo  | 2015 | Nigeria | All             | 400         | 31.5%                | [13]|
| 4     | Adejo    | 2017 | Nigeria | All             | 121         | 27.2%                | [14]|
| 5     | Nurat    | 2015 | Nigeria | All             | 140         | 25%                  | [15]|
| 6     | Menza    | 2013 | Kenya   | All             | 220         | 42.7%                | [16]|
| 7     | Waikhom  | 2020 | Ghana   | All             | 176         | 31%                  | [17]|
| 8     | Tsega    | 2019 | Ethiopia| All             | 384         | 25%                  | [18]|
| 9     | Olughenha| 2014 | Nigeria | All             | 100         | 36%                  | [19]|
| 10    | Mohamed  | 2014 | Sudan   | All             | 300         | 16.6%                | [20]|
| 11    | Tchelougu| 2013 | Togo    | All             | 302         | 30.77%               | [21]|
| 12    | Herieka  | 2004 | Sudan   | All             | 151         | 13.9%                | [22]|
| 13    | Moses    | 1996 | Kenya   | All             | 291         | 26.2%                | [23]|
| 14    | Mukasa   | 2015 | Uganda  | All             | 456         | 45.4%                | [24]|
| 15    | I. Sangaré| 2017| Burkina Faso | All | 229 | 22.71% | [25]|
| 16    | Dennis   | 2019 | Ghana   | All             | 589         | 36.5%                | [26]|
also provides an insight into the possible reasons behind the variations in VVC prevalence between these studies. Out of 4,185 pregnant women from 8 different countries, the overall prevalence of VVC was 29.2% (CI 95%: 24.8 – 33.5). Pregnant women from eastern regions were more susceptible to VVC (34.4%, CI 95%: 23.8 – 45.6) than women from western (29.9%, CI 95%: 26.9 – 32.9) and central regions (15.3%, CI 95%: 11.5 – 19.1).

The pooled prevalence in this analysis is more, less, or in line with previous investigations conducted worldwide. Our results were comparable with the studies conducted in Argentina (25%), the Kingdom of Saudi Arabia (34%), and Jamaica (31%) [11-13]. However, a relatively high prevalence was reported in Lebanon (42%) and Brazil (44%) [14-16], and a low prevalence was observed in China (13%) and Kuwait (20%) [17]. These disparities across the studies are primarily attributed to various factors including sampling, clinical settings, study design and methodology, and variations in risk factors. Unfortunately, we were unable to get data from many countries due to the fact that the majority of reported prevalence was from low to middle-income countries. This indicates that either these infections were associated with a poor population or these populations were more inclined towards childbearing, inclining the researchers to investigate the complications during pregnancy. However, more scientific evidence is the need of the hour to draw a firm conclusion.

A higher prevalence was also reported by studies in some African countries (not included in this study since they did not meet the inclusion criteria) such as Tanzania (65%), Cameroon (55%), and Libya (43%) [18-20]. The probable reason for such discrepancies is the selection bias since all these studies were conducted in symptomatic pregnant women. It is pertinent to mention that authors in the included studies managed to analyze the results by separating the symptomatic and non-symptomatic patients. Sangaré et al. reported the overall prevalence to be 22%, however, the prevalence among symptomatic pregnant women was 58% (\( p < 0.001 \)) [21]. Such reported prevalence implies the necessity and utility to define an appropriate study population while conducting epidemiological studies on VVC.

Though the estimated pooled prevalence in this study is in concordance with the available literature, significant heterogeneity was observed (\( I^2 = 89.8\% \)). Several attempts have been made to explore the sources of heterogeneity using subgroup and meta-regression analysis. The variation between the studies was not surprising as is an attempt to pool results of observational studies. This paradox is in line with the previous meta-analysis which investigates the prevalence of BV and STIs in the Africa regions, and the prevalence of BV worldwide. Interestingly, both studies concluded that the high prevalence of BV in the eastern region and low in the central and western regions [7,8].

Since *C. albicans* is the most common causative pathogen for VVC, the isolation of non-*C. albicans* species from vaginal swab is rare [2]. Detection of *C. albicans* is somewhat easier and could be done using wet preparation and germ tube, however, confirming non-*C. albicans* isolates require extra-diagnostic techniques such as culture on chromogenic media, API kits, sugar assimilation tests, and PCR [22,23]. In this context, diagnostic cost and lack of expertise might be another reason that most of the investigators have primary focus on *C. albicans*. The association between the method of detection and prevalence of VVC (\( p = 0.001 \)) is an interesting aspect of this study. The higher prevalence was reported in Kenya (42%) and Uganda (45%) [24,25] and interestingly these studies adopted either API kits or chromogenic media and sugar assimilation tests as identification techniques. This can be compared to a lower prevalence reported in Kenya (25%) in which wet preparation was used to identify VVC [26]. Moreover, an Ethiopian study which had used chromogenic media for detecting *Candida* species reported the 25% prevalence of VVC among pregnant women [27]. Since pregnancy is a well-established risk factor for VVC, a higher prevalence (41%) was also reported by another study on non-pregnant women, in which the authors adopted an automated VITEK 2

| Coefficient | CI Lower Bound | CI Upper Bound | Std. error | \( p \) value |
|-------------|----------------|----------------|-------------|---------------|
| Intercept   | -6.651         | -21.388        | 8.086       | 7.519         | 0.367         |
| Year of publication | 0.003 | -0.004         | 0.011       | 0.004         | 0.316         |
| Intercept   | 0.199          | 0.108          | 0.290       | 0.046         | < 0.001       |
| Sample size | 0.000          | 0.000          | 0.001       | < 0.001       | 0.048         |
| Intercept   | 0.17           | 0.094          | 0.246       | 0.039         | < 0.001       |
| Method of detection | 0.074 | 0.03           | 0.119       | 0.023         | < 0.001       |

Table 2. Result of Meta-regression using Year of publication, Sample size, and Method of detection as a continuous variable, Mixed-effect model.
compact system to diagnose VVC [28]. The two studies from Sudan reported the lowest prevalence of VVC (13% and 16%) [29,30]. Interestingly, these studies used wet preparation for detection. However, a slightly higher proportion was also estimated in another study from Sudan (33%) [31]. The possible reason for this variation is that the later used chromogenic media which recovered 90 out of 104 isolates (86.2%). In the same study when germ tube and wet preparation were used only 72 isolates (69.2%) were identified [31]. Considering the recently observed mycological shift of Candida species from C. albicans to a non-C. albicans, this finding is alarming and points toward the necessity of using identification techniques other than wet preparation and germ tube test that are able to identify at least the medically important Candida species during the diagnostics workup of VVC.

The development of VVC depends on several host risk factors such as stages of pregnancy and age of the pregnant women. Intra-population differences in these risk factors were not similar across the studies which in turn might precipitate the overall heterogeneity. During the analysis, we noticed that pregnant women in the third trimester were at higher risk than those in the first and second trimester (nine studies reported detailed prevalence at each trimester) [21,24,26,27,32-37]. Out of 800 pregnant women with VVC, 416 (52%) were in the third trimester, 273 (34.23%) in the second, and 111 (13.87%) in the first trimester. The results are in concordance with the findings, of previous studies [5,38]. It is important to note that the studies with high prevalence included a higher sample of pregnant women in the third trimester, however, results remain insignificant during the analysis (p = 0.916). It is pertinent to mention that there was a relationship between the age of pregnant women and the prevalence of VVC. Eight studies gave sufficient data to ascertain such association (mean age from 23 to 29) [21,26,27,29,32,36,37,39]. These studies reveal that the prevalence of VVC increases with the increasing age of the women (p = 0.019). These findings necessitate the vigilant monitoring of pregnant women with advanced age and in the third trimester, as they are most likely to develop the infection due to increasing age. Moreover, clinicians should consider the preventable approaches for this particular age group.

Our results show that the sources of variation are not only limited to the study design, sampling, and methods of detection. Other risk factors such as the use of antimicrobials could also affect the finding. Most of the studies did not provide complete data to analyse this factor. However, data from some studies gave a clue about of possible contribution of antimicrobial use among patients. A report from Nigeria found that the prevalence increased from 30% to 80% with the use of antibiotic (p = 0.035) [36]. Likewise, administration of antibiotics was reported to increase the prevalence from 21% to 46% (p = 0.003) [27]. Additionally, type, duration, and route of administration of antibiotics also affect the incidence of VVC differently. This finding indicates that slight differences in a clinical setting of the study populations will have a great impact on the prevalence of VVC. These confounding factors should be considered while designing and/or comparing cross-sectional studies. Future research should consider the use of antimicrobials as a risk factor of VVC.

It is important to note that VVC occurs in an area where huge microbial diversity exists, i.e., vaginal microflora, the occurrence of this phenomenon is an essential cause of variation that must be considered. Indeed, VVC has been reported by some studies to be associated with a loss of Lactobacilli population [40,41] that are important beneficial microorganisms. Factors that impact vaginal microflora such as geographical diversity might also affect the susceptibility to VVC. These factors may cause variability in the prevalence of VVC. These findings are in line with data from Burkina Faso where a low prevalence was reported (22%) in comparison to Kenya and Uganda (42% and 45% respectively) [21]. Vaginal infections such as bacterial vaginosis are reportedly low in Burkina Faso and higher in Eastern regions of Africa [8]. Moreover, microbiome data analysis from related studies revealed that, pregnant women from Burkina Faso harbor a higher population of Lactobacilli in comparison to women from the eastern region, in which Parvimonas species Types 1 and 2, Gemellaa saccharolytica, Mycoplasma hominis, Leptotrichia Sneathia, Eggerthella species Type1, and vaginal Megasphaera species were the dominant vaginal microflora [42].

Beside the dramatic increase in the rate of deep and superficial fungal infection in the last two decades, several factors such as high cost, toxicity, and availability of limited antifungal agents have complicated the clinical management of VVC [43]. However, the emergence of resistant strains and the development of secondary resistance by species that were known to be sensitive is the main challenge for the researcher. Another notable observation was that high resistance was mainly attributed to the NCA [32]. It was observed that C. albicans was 0.61% resistant to clotrimazole, whereas C. glabrata and C. famata were found to be 50% and 36% resistant, respectively. C. krusie showed a resistance of 71.43% to fluconazole.
This indicates a high resistance rate of NCA compare to C. albicans. In addition, the prevalence of NCA was found to be increasing compared to that of C. albicans. According to a report from Burkina-Faso where the prevalence of VVC was 22.71%, NCA accounted for 59.61% [21].

There have been many attempts to overcome the resistance by developing new compounds and/or potentiating the existing antifungal agents to increase the activity against MDR Candida species. An example is the oil macerates of North Sardinia plants that showed interesting activity against C. krusie, C. glabrata, and C. parasilosis [43]. In addition, Ruta graveolens essential oil has potent fungicidal activity against C. tropicalis and C. albicans that was suggested to be attributed to increased intracellular leakage of macromolecules. Ruta graveolens was also noted to have a synergistic effect with amphotericin B [44]. Another strategy focuses on increasing the efficacy of antifungal agents by inhibiting the ABC transport pump that is responsible for the efflux of the drug outside the cell. The P-glycoproteins which have been screened against different Candida species gave a satisfying result when combined with fluconazole [45]. Recently, the activity of four different Styryloquinoline compounds as ABC transport pump inhibitors and the role of the hydroxyl group attached to the quinolone moiety was investigated, the study reveals that the role of the hydroxyl group dramatically increased the antifungal activity against a wild and mutant strain of Candida species. Additionally, the same compound demonstrates a strong synergistic action when combined with fluconazole [46].

This study is accompanied by a few limitations which must be considered while interpreting the results. The studies included in this review do not entirely represent the whole of Africa. There is a dire need to conduct epidemiological estimation in the African regions where data is currently lacking. Furthermore, the impact of certain moderators was practically impossible due to the unavailability of some data (stages of pregnancy) and inconsistency of the data (age level of the participating pregnant women).

Conclusions
This study indicated a high prevalence of VVC in Eastern regions of Africa, followed by western and Northern regions. Moreover, a higher prevalence was reported in studies where identification techniques were able to screen most of Candida species. Variations across the studies were detected and the sources of heterogeneity and potential reasons of such variations were explored. Further large-scale studies are needed in other regions of Africa for which epidemiological data on VVC is currently lacking.

Acknowledgements
We would like to thank Dr. Mazin Yousef from International University of Africa, Faculty of Pharmacy, Department of Pharmacology for providing assistance during data extraction and analysis.

References
1. das Neves J, Pinto E, Teixeira B, Dias G, Rocha P, Cunha T, Santos B, Amaral MH, Bahia MF (2008) Local treatment of vulvovaginal candidosis. Drugs 68: 1787-1802.
2. Makanjuola O, Bongomin F, Fayemwio SA (2018) An update on the roles of non-albicans Candida species in vulvovaginitis. J Fungi 4: 121.
3. Rossoni RD, Barbosa JO, Vilela SFG, dos Santos JD, de Barros PP, de Azevedo Prata MC, Anbinder AL, Fuchs BB, Jorge AOC, Mylonakis E (2015) Competitive interactions between C. albicans, C. glabrata and C. krusei during biofilm formation and development of experimental candidiasis. PLoS One 10: e0131700.
4. Silva S, Henriques M, Hayes A, Oliveira R, Azerojo J, Williams DW (2011) Candida glabrata and Candida albicans coinfection of an in vitro oral epithelium. J Oral Pathol Med 40: 421-427.
5. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azerojo J, Silva S (2016) Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol 42: 905-927.
6. Sobel JD (2007) Vulvovaginal candidiasis. Lancet 369: 1961-1971.
7. Torrone EA, Morrison CS, Chen P-L, Kwok C, Francis SC, Hayes RJ, Looker KJ, McCormack S, McGrath N, van de Wijgert JH (2018) Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies. PLoS Med 15: e1002511.
8. Kenyon C, Colebunders R, Crucitti T (2013) The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol 209: 505-523.
9. Goldenberg RL, Culhane JF, Iams JD, Romero R (2008) Epidemiology and causes of preterm birth. Lancet 371: 75-84.
10. Roberts CL, Morris JM, Rickard KR, Giles WB, Simpson JM, Kotsiou G, Bowen JR (2011) Protocol for a randomised controlled trial of treatment of asymptomatic candidiasis for the prevention of preterm birth [ACTRN12610000607077]. BMC Pregnancy Childbirth 11: 1-9.
11. Mucci MJ, Cuestas ML, Cervetto MM, Landaburu MF, Mujica MT (2016) A prospective observational study of vulvovaginitis in pregnant women in Argentina, with special reference to candidiasis. Mycoses 59: 429-435.
12. Kamara P, Hylton-Kong T, Brathwaite A, Rosario GRD, Kristensen S, Patrick N, Weiss H, Figueroa PJ, Vermund SH, Jolly PE (2000) Vaginal infections in pregnant women in Jamaica: prevalence and risk factors. Int J STD AIDS 11: 516-520.
13. Venugopal D, Husain K, Mustafa S, Sabeen S (2020) Epidemiology, risk factors and antimicrobial profile of vulvovaginal candidiasis (VVC): A study among women in the central region of Saudi Arabia. J Mycol Med 31: 101049.

14. Ghaddar N, El Roz A, Ghsein G, Ibrahim J-N (2019) Emergence of vulvovaginal candidiasis among Lebanese pregnant women: Prevalence, risk factors, and species distribution. Infect Dis Obstet Gynecol 2019.

15. Ghaddar N, Anastasiadis E, Halimeh R, Ghaddar A, Dhar R, AlFouzan W, Yusef H, El Chaar M (2020) Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon. BMC Infect Dis 20: 1-9.

16. Dias LB, Melhem MdSC, Szesz WS, Meirelles Filho J, Hahn RC (2011) Vulvovaginal candidiasis in Mato Grosso, Brazil: Pregnancy status, causative species and drugs tests. Braz. J. Microbiol 42: 1300-1307.

17. Zhai Y, Liu J, Zhou L, Ji T, Meng L, Gao Y, Liu R, Wang X, Li L, Lu B (2018) Detection of Candida species in pregnant Chinese women with a molecular beacon method. J Med Microbiol 67: 783.

18. Mushki MF, Momole A, Mshana SE (2019) Candida vaginitis among symptomatic pregnant women attending antenatal clinics in Mwanza, Tanzania. BMC Res Notes 12: 1-5.

19. Altayyar IA, Alsanosi AS, Osman NA (2016) Prevalence of vaginal candidiasis among pregnant women attending different gynecological clinic at South Libya. Eur J Exp Biol 6: 25-29.

20. Toua V, Djauoda M, Gaké B, Mnye DE, Christie E, Tambe E, Akindoh VV, Njine T (2013) Prevalence of vulvovaginal candidiasis amongst pregnant women in Maroua (Cameroon) and the sensitivity of Candida albicans to extracts of six locally used antifungal plants. Int Res J Microbiol 4: 89-97.

21. Sangaré I, Sirima C, Bamba S, Zida A, Cissé M, Bazié W, Sanou S, Dao B, Menan H, Guiguemdé R (2018) Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso. J Mycol Med 28: 186-192.

22. Leaw SN, Chang HC, Barton R, Bouchara JP, Chang TC (2007) Identification of medically important Candida and non-Candida yeast species by an oligonucleotide array. J Clin Microbiol 45: 2220-2229.

23. Neppelenbroek K, Seo R, Urban V, Silva S, Dovigo L, Jorge J, Campanha N (2014) Identification of Candida species in the clinical laboratory: A review of conventional, commercial, and molecular techniques. Oral Dis 20: 329-344.

24. Nelson M, Wanjiru W, Margaret MW (2013) Prevalence of vaginal candidiasis and determination of the occurrence of Candida species in pregnant women attending the antenatal clinic of Thika District Hospital, Kenya. Open J Med Microbiol 2013.

25. Mukasa KJ, Herbert I, Daniel A, Sserunkuma KL, Joel B, Frederick B (2015) Antifungal susceptibility patterns of vulvovaginal Candida species among women attending antenatal clinic at Mbarara Regional Referral Hospital, South Western Uganda. Br Microbiol Res Journal 5: 322.

26. Thomas T, Choudhri S, Kariuki C, Moses S (1996) Identifying cervical infection among pregnant women in Nairobi, Kenya: Limitations of risk assessment and symptom-based approaches. Sex Transm Infect 72: 334-338.

27. Tseg A, Mekonnen F (2019) Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia. BMC Pregnancy Childbirth 19: 1-8.

28. Seyoum E, Bitew A, Mihret A (2020) Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal susceptibility profile in Ethiopia. BMC Infect Dis 20: 1-9.

29. Ortashi O, El Khidir I, Herieka E (2004) Prevalence of HIV, syphilis, Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis and candidiasis among pregnant women attending an antenatal clinic in Khartoum, Sudan. J Obstet Gynaecol 24: 513-515.

30. Abdelaziz ZA, Ibrahim ME, Bilal NE, Hamid ME (2014) Vaginal infections among pregnant women at Omdurman Maternity Hospital in Khartoum, Sudan. J Infect Dev Ctries 8: 490-497. doi:10.3855/jidc.3197.

31. Nemery HM (2019) Phenotypic characterization of vaginal candidiasis in Sudanese pregnant women. Afr J Med Sci 4.

32. Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, Doku JG, Kasu ES, Mensah P, Agede CY (2020) Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: Species identification and antifungal susceptibility of Candida isolates. BMC Pregnancy Childbirth 20: 1-14.

33. Okonkwo N, Umeanaeto P (2010) Prevalence of vaginal candidiasis among pregnant women in Nnewi Town of Anambra State, Nigeria. Afr Res Rev 4.

34. Ezeigo O, Anolue F, Nnadozie I (2015) Vaginal candidiasis infection among pregnant women in Aba, Abia state, Nigeria. J Adv Med: 1-6.

35. Nurat AA, Babalola G, Shittu M, Tijani M, Adekola S (2015) Detection and epidemiology of vulvovaginal candidiasis among asymptomatic pregnant women attending a tertiary hospital in Ogbomoso, Nigeria. Int J Biomed Res 6: 518-523.

36. Olowe O, Makanjuola O, Olowe R, Adekanle D (2014) Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria. Euro J Microbiol Immunol 4: 193-197.

37. Konadu DG, Owusu-Ofori A, Yidana Z, Boadu F, Iddrisu LF, Adu-Gyasi D, Dosoo D, Awuley RL, Owusu-Agyei S, Asante KP (2019) Prevalence of vulvovaginal candidiasis, bacterial vaginosis and trichomoniasis in pregnant women attending antenatal clinic in the middle belt of Ghana. BMC Pregnancy Childbirth 19: 341.

38. Susir V, Foessleitner P, Kiss H, Farr A (2020) Vaginal candidiasis: Current concepts, challenges and perspectives. J Fungi 6: 267.

39. Tchelouougou D, Karou D, Kpotsra A, Balaka A, Assih M, Bamoké M, Katawa G, Anani K, Simpore J, de Souza C (2013) Vaginal infections in pregnant women at the regional hospital of Sokode (Togo) in 2010 and 2011. Med Sante Trop 23: 49.

40. McClelland RS, Richardson BA, Hassan WM, Graham SM, Kiari J, Baeten JM, Mandaliya K, Jaoko W, Ndinya-Achola JO, Holmes KK (2009) Prospective study of vaginal bacterial flora and other risk factors for vaginal candidiasis. J Infect Dis 199: 1883-1890.

41. Liu M-B, Xu S-R, He Y, Deng G-H, Huang X-M, Liu R, Wang X, Ouyang C-Y, Zhou H-W (2013) Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS One 8: e79812.

42. Odogwu NM, Olayemi OO, Omigbodun AO (2020) The vaginal microbiome of sub-Saharan African women: Revealing important gaps in the era of next-generation sequencing. PeerJ 8: e9684.
43. Donadu M, Usai D, Marchetti M, Usai M, Mazzarello V, Molicotti P, Montesu M, Delogu G, Zanetti S (2020) Antifungal activity of oils macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. Nat Prod Res 34: 3280-3284.

44. Donadu MG, Peralta-Ruiz Y, Usai D, Maggio F, Molina-Hernandez JB, Rizzo D, Bussu F, Rubino S, Zanetti S, Paparella A (2021) Colombian essential oil of ruta graveolens against nosocomial antifungal resistant candida strains. J Fungi 7: 383.

45. Usai D, Donadu M, Bua A, Molicotti P, Zanetti S, Piras S, Corona P, Ibba R, Carta A (2019) Enhancement of antimicrobial activity of pump inhibitors associating drugs. J Infect Dev Ctries 13: 162-164. doi: 10.3855/jidc.11102.

46. Cieslik W, Szczepaniak J, Krasowska A, Musiol R (2020) Antifungal styryloquinolines as Candida albicans efflux pump inhibitors. Styryloquinolines are ABC transporter inhibitors. Molecules 25: 345.

Corresponding authors
Ahmed Osman Mohamed, Lecturer
International University of Africa, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, P.O. Box 407, Khartoum, Sudan.
Tel: 00249901069067
Email: Ahmedkunna@iua.edu.sd

Malik Suliman Mohamed, Associated Professor
Jouf University, College of Pharmacy, Department of Pharmaceutics, P.O. Box 72341, Al-Jouf Province, Kingdom of Saudi Arabia.
Email: msmustafa@ju.edu.sa

Conflict of interests: No conflict of interests is declared.
Annex – Supplementary Items

Supplementary Table 1. Methodological Quality Assessment as per Joanna Briggs Institute (JBI) Critical Appraisal Checklist for studies.

| Study ID      | Was the sample frame appropriate to address the target population? | Were study participants sampled in an appropriate way? | Was the sample size adequate? | Were the study subjects and the setting described in detail? | Was the data analysis conducted with sufficient coverage of the identified sample? | Were valid methods used for the identification of the condition? | Was the condition measured in a standard, reliable way for all participants? | Was there appropriate statistical analysis? | Was the response rate adequate, and if not, was the low response rate managed appropriately? |
|---------------|---------------------------------------------------------------------|--------------------------------------------------------|-------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------------------------|
| Okonkwo       | Y                                                                   | Y                                                      | Y                             | NA                                                              | N                                                                       | N                                                                      | N                                                                            | Y                                               | NA                                                                            |
| Donbraye      | Y                                                                   | N                                                      | N                             | N                                                              | Y                                                                       | Y                                                                      | N                                                                            | N                                               | NA                                                                            |
| Ezeigbo       | Y                                                                   | Y                                                      | Y                             | N                                                              | NA                                                                      | N                                                                       | N                                                                            | Y                                               | NA                                                                            |
| Adejo         | Y                                                                   | N                                                      | N                             | N                                                              | NA                                                                      | N                                                                       | N                                                                            | N                                               | NA                                                                            |
| Nurat         | Y                                                                   | N                                                      | N                             | N                                                              | NA                                                                      | N                                                                       | N                                                                            | N                                               | NA                                                                            |
| Menza         | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | Y                                                                       | N                                                                            | Y                                               | NA                                                                            |
| Waikhom       | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | Y                                                                       | Y                                                                            | Y                                               | NA                                                                            |
| Tsega         | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | Y                                                                       | N                                                                            | N                                               | NA                                                                            |
| Olugbenga     | Y                                                                   | N                                                      | N                             | N                                                              | NA                                                                      | N                                                                       | Y                                                                            | N                                               | NA                                                                            |
| Mohamed       | Y                                                                   | Y                                                      | N                             | Y                                                              | NA                                                                      | N                                                                       | Y                                                                            | Y                                               | NA                                                                            |
| Tchelougo     | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | N                                                                       | Y                                                                            | Y                                               | NA                                                                            |
| Herieka       | Y                                                                   | Y                                                      | N                             | N                                                              | NA                                                                      | N                                                                       | N                                                                            | N                                               | NA                                                                            |
| Moses         | Y                                                                   | Y                                                      | N                             | Y                                                              | NA                                                                      | N                                                                       | N                                                                            | N                                               | NA                                                                            |
| Mukasa        | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | Y                                                                       | Y                                                                            | N                                               | NA                                                                            |
| I. Sangaré    | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | Y                                                                       | Y                                                                            | Y                                               | NA                                                                            |
| Dennis        | Y                                                                   | Y                                                      | Y                             | Y                                                              | NA                                                                      | Y                                                                       | Y                                                                            | Y                                               | NA                                                                            |

Y: Yes; N: No; U: Unclear; NA: Not/Applicable

Supplementary Figure 1. Meta-regression of VVC based on Method of detection.

Supplementary Figure 2. Meta-regression of VVC based on Sample size.

1: wet preparation and germ tube; 2: Chromogenic media; 3: ABI kits or chromogenic media + sugar assimilation.